J&J Advances Pipeline With Yondelis, Carisbamate Filings
This article was originally published in The Pink Sheet Daily
Executive Summary
Company is on track to achieve goal of filing seven to 10 new products from the beginning of 2008 through end of 2010, CEO Weldon says.
You may also be interested in...
A Double Dose of Doxil: FDA Advisory Committee Will Review Two Applications
Centocor’s Yondelis application for relapsed ovarian cancer is the headliner for the July 15 ODAC meeting, but the cardiac safety profile of Doxil could take center stage.
A Double Dose of Doxil: FDA Advisory Committee Will Review Two Applications
Centocor’s Yondelis application for relapsed ovarian cancer is the headliner for the July 15 ODAC meeting, but the cardiac safety profile of Doxil could take center stage.
CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana
New firm’s management team is looking for pharma partners to validate its expertise, attract venture funding while parent CTI struggles to stay in business.